Fulgent Genetics (FLGT)

Fulgent’s main business is its laboratory services operation, which generates the majority of its revenue. This business includes technical testing performed in certified laboratories as well as professional interpretation of results by licensed physicians when required. Its testing menu has included hereditary disease testing, oncology testing, reproductive health testing, carrier screening, and other molecular diagnostics. The company became more widely known during the COVID-19 pandemic through large-scale testing services, but its longer-term identity remains tied to genetics, precision medicine, and advanced diagnostics.

The company also operates a therapeutic development business focused on drug candidates for cancer and related areas. This gives Fulgent a broader healthcare profile than a pure-play testing laboratory, though the therapeutics segment carries the higher research, clinical, and regulatory risks typical of drug development.

Fulgent earns the vast majority of its revenue in the United States, with a smaller contribution from international markets. Its customers can include physicians, hospitals, health systems, government agencies, and commercial partners. For investors, Fulgent Genetics offers exposure to the expanding use of genomic information in medicine, including the shift toward earlier detection, more targeted diagnostics, and personalized treatment decisions. Its performance depends on testing volumes, reimbursement, laboratory execution, competition, and progress within its oncology development pipeline.